<a href="https://www.fiercebiotech.com/medtech/foundation-medicine-links-fulgent-genetics-offer-new-gene-test" hreflang="en">Foundation Medicine links with Fulgent Genetics to offer new gene test</a>
Foundation Medicine has partnered with Fulgent Genetics to launch a new pharmacogenetic diagnostic test called FoundationOne PGFx, which helps determine how patients metabolize drugs, enhancing treatment effectiveness and minimizing adverse reactions. This test will be available in the U.S. and is designed to support healthcare providers in making informed treatment decisions, particularly in oncology.
Foundation Medicine's partnership with Fulgent Genetics to offer the FoundationOne PGx diagnostic test represents a significant advancement in precision medicine, particularly in oncology. This pharmacogenetic test enhances personalized treatment plans by identifying genetic variations that affect drug metabolism, thereby reducing adverse drug reactions and improving treatment efficacy. For professionals in healthtech and biotech, this collaboration highlights the growing importance of integrating genomic profiling into clinical practice to optimize drug therapies and patient outcomes.